A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Baird lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $320 from $325 and keeps an Underperform rating on the shares. The ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

challenges in the U.S. healthcare system, and the inherent risks of drug development have contributed to the sector's underperformance relative to the broader markets during this period. Vertex ...

Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks ... it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty ...

Vertex Pharmaceuticals (VRTX ... we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, stretching ...

Vertex Pharmaceuticals Inc. (NASDAQ ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if VRTX is one of these AI-selected gems? Check out our ProPicks platform ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Alibaba Group Holding (BABA) stock is scaling the price charts Wednesday after the Chinese e-commerce giant released a new version of its open-source artificial intelligence (AI) model ...

DeepSeek-R1 is 20 to 50 times more affordable to use than OpenAI's o1 model. There's a new entrant in the Artificial Intelligence chatbot market from China. It is competing with giants like OpenAI ...